Väljaminev kiriAvalik
Farmakopöa töökava asjus
Ravimiamet · 24. oktoober 2025
- Viit
- REP-1/5619-2
- Registreeritud
- 24. oktoober 2025
- Dokumendi liik
- Väljaminev kiri
- Adressaat
- European Directorate for the Quality of Medicines & HealthCare
- Funktsioon
- REP Euroopa Farmakopöaga seotud asjaajamine
- Sari
- REP-1 Euroopa Farmakopöa alane kirjavahetus
- Toimik
- REP-1/2025
- Vastutaja
- Signe Leito (RA, Peadirektori asetäitja valdkond, Labor)
Sisu (failidest)
Addition of Pegaspargase powder for injection monograph to the Work
Programme of Group 6
page 1 / 3
Q1-4 (4392)
NPA: (55072)
Type: (!/list-dropdown)
A10 - Estonia (EE)
Please choose: (55073)
Type: (L/list-radio)
In favour of the addition of Pegaspargase powder for injection monograph to the work programme
A1
If opposed to this addition to the work programme, please state why (55074)
Type: (T/text-long)
-
page 2 / 3
If you are in favour of this addition, please indicate any other known manufacturers to be
contacted (with contact details if available) (55075)
Type: (T/text-long)
n.a
Please share any information related to the criticality of pegaspargase in your country or any other remark:
(55076)
Type: (T/text-long)
-
page 3 / 3